Federated Hermes
RLAY icon

Federated Hermes’s Relay Therapeutics RLAY Stock Holding History

Federated Hermes’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$122K Buy
+6,500
New +$94.4K ﹤0.01% 1590
2025
Q4 		– Sell
-36,000
Closed -$188K – 2184
2025
Q3 		$188K Sell
36,000
-35,217
-49% -$134K ﹤0.01% 1517
2025
Q2 		$246K Sell
71,217
-25,096
-26% -$74.6K ﹤0.01% 1462
2025
Q1 		$252K Buy
96,313
+46,213
+92% +$181K ﹤0.01% 1460
2024
Q4 		$206K Buy
50,100
+42,231
+537% +$230K ﹤0.01% 1480
2024
Q3 		$55.7K Sell
7,869
-304,575
-97% -$2.28M ﹤0.01% 1637
2024
Q2 		$2.04M Sell
312,444
-24,046
-7% -$164K ﹤0.01% 919
2024
Q1 		$2.79M Buy
+336,490
New +$3.28M 0.01% 850
2022
Q1 		– Sell
-600,000
Closed -$18.4M – 2289
2021
Q4 		$18.4M Hold
600,000
– – 0.03% 510
2021
Q3 		$18.9M Hold
600,000
– – 0.04% 480
2021
Q2 		$22M Sell
600,000
-218,309
-27% -$7.19M 0.04% 455
2021
Q1 		$28.3M Buy
818,309
+250,000
+44% +$10.9M 0.05% 408
2020
Q4 		$23.6M Buy
568,309
+68,309
+14% +$3.09M 0.05% 428
2020
Q3 		$21.3M Buy
+500,000
New +$19.1M 0.05% 396

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Federated Hermes's RLAY Position: Q2 2026 in Review

Federated Hermes opened a new position in Relay Therapeutics (RLAY) in Q2 2026: 6,500 shares worth $122K. The stake represents ﹤0.01% of the portfolio and ranks #1590 among its holdings. This is a return to the name: Federated Hermes previously reported a position in RLAY as recently as Q3 2025.

Federated Hermes first reported a position in RLAY in Q3 2020 and has held it in 14 quarters since. The position peaked at $28.3M in Q1 2021. 258 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Federated Hermes held 6,500 shares of Relay Therapeutics worth $122K as of Q2 2026.
  • Relay Therapeutics was a new Federated Hermes position in Q2 2026.
  • Relay Therapeutics made up ﹤0.01% of Federated Hermes's portfolio in Q2 2026, its #1590 holding.
  • Federated Hermes first reported a position in Relay Therapeutics in Q3 2020 and has held it in 14 quarters since.
  • Federated Hermes's Relay Therapeutics position peaked at $28.3M in Q1 2021.
  • 258 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.